Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current Treatment Options in Oncology

• Publication date

  2017-02-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s11864-017-0449-1PMID 28229364
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of oncogene rearrangement patterns on outcomes in patients with double‐hit non‐Hodgkin lymphoma

  2016cited by this paper
• B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.

  2016cited by this paper
• A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

  2016cited by this paper
• Molecular Monitoring of Cell-Free Circulating Tumor DNA in Non-Hodgkin Lymphoma.

  2016cited by this paper
• Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.

  2016cited by this paper
• Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.

  2016cited by this paper
• EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment.

  2015cited by this paper
• 5-Azacitidine induces demethylation of PTPL1 and inhibits growth in non-Hodgkin lymphoma

  2015cited by this paper
• Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance)

  2015cited by this paper
• Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) With Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results From the Pyramid Trial (NCT00931918).

  2015cited by this paper
• Novel targeted therapies in diffuse large B-cell lymphoma.

  2015cited by this paper
• Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.

  2015cited by this paper
• All in the family: Clueing into the link between metabolic syndrome and hematologic malignancies.

  2015cited by this paper
• Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy

  2015cited by this paper
• B-cell receptor signaling in diffuse large B-cell lymphoma.

  2015cited by this paper
• Synergistic Induction of Apoptosis in High-Risk DLBCL by BCL2 Inhibition with ABT-199 Combined With Pharmacologic Loss of MCL1

  2015cited by this paper
• AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

  2015cited by this paper
• Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.

  2015cited by this paper
• Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review

  2015cited by this paper
• Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma

  2015cited by this paper
• Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.

  2015cited by this paper
• Double hit lymphoma: the MD Anderson Cancer Center clinical experience

  2014cited by this paper
• Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.

  2014cited by this paper
• Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma

  2014cited by this paper
• High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells

  2014cited by this paper
• Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

  2014cited by this paper
• EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.

  2014cited by this paper
• PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

  2014cited by this paper
• High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial

  2014cited by this paper
• Diffuse large B-cell lymphoma—treatment approaches in the molecular era

  2014cited by this paper
• Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.

  2014cited by this paper
• Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors

  2014cited by this paper
• A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL).

  2014cited by this paper
• Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

  2014cited by this paper
• A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.

  2014cited by this paper
• A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL

  2014cited by this paper
• MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.

  2013cited by this paper
• The hematologic mission and scope of the Journal in 2013: Blood, a podium for clinical studies and a podium for experimental research in hematology.

  2013cited by this paper
• Biomimetic, synthetic HDL nanostructures for lymphoma

  2013cited by this paper
• Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma

  2013cited by this paper
• Ibrutinib and novel BTK inhibitors in clinical development

  2013cited by this paper
• Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.

  2013cited by this paper
• Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

  2013cited by this paper
• PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma

  2013cited by this paper
• Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.

  2013cited by this paper
• EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.

  2013cited by this paper
• EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains

  2013cited by this paper
• The Bruton tyrosine kinase (BTK) inhibitor PCI‐32765 synergistically increases proteasome inhibitor activity in diffuse large‐B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib

  2013cited by this paper
• Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

  2013cited by this paper
• Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ, in patients with relapsed/refractory lymphoma.

  2013cited by this paper
• A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

  2012cited by this paper
• Lenalidomide efficacy in activated B‐cell‐like subtype diffuse large B‐cell lymphoma is dependent upon IRF4 and cereblon expression

  2012cited by this paper
• Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy

  2012cited by this paper
• Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

  2012cited by this paper
• The PIM kinases in hematological cancers

  2012cited by this paper
• Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.

  2012cited by this paper
• Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

  2012cited by this paper
• The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study

  2012cited by this paper
• Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma.

  2012cited by this paper
• EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

  2012cited by this paper
• JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

  2012cited by this paper
• BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab

  2011cited by this paper
• Targeting MYC dependence in cancer by inhibiting BET bromodomains

  2011cited by this paper
• Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.

  2011cited by this paper
• Frequent mutation of histone modifying genes in non-Hodgkin lymphoma

  2011cited by this paper
• Cholesterol esters as growth regulators of lymphocytic leukaemia cells

  2011cited by this paper
• Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

  2011cited by this paper
• Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

  2010cited by this paper
• NF-κB/STAT3/PI3K signaling crosstalk in iMycEμ B lymphoma

  2010cited by this paper
• Inactivating mutations of acetyltransferase genes in B-cell lymphoma

  2010cited by this paper
• Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

  2010cited by this paper
• Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

  2010cited by this paper
• Dynamic CO-Localization of GATA1, NFE2, and EKLF and Changes in Gene Expression During Hematopoiesis

  2010cited by this paper
• Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

  2010cited by this paper
• Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin

  2010cited by this paper
• Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.

  2009cited by this paper
• HDAC inhibitor-based therapies and haematological malignancy.

  2009cited by this paper
• Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment.

  2009cited by this paper
• Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

  2008cited by this paper
• Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study

  2008cited by this paper
• Stromal gene signatures in large-B-cell lymphomas.

  2008cited by this paper
• Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.

  2008cited by this paper
• The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.

  2007cited by this paper
• From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 28, 2013. For personal use only.

  2007cited by this paper
• Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase

  2007cited by this paper
• The JAK-STAT pathway: a therapeutic target in hematological malignancies.

  2006cited by this paper
• Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.

  2005cited by this paper
• BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma.

  2004cited by this paper
• Genome-wide analysis of STAT target genes: Elucidating the mechanism of STAT-mediated oncogenesis

  2004cited by this paper
• Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.

  2004cited by this paper
• B cell antigen receptor signaling 101.

  2004cited by this paper
• Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells

  2001cited by this paper
• Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

  2000cited by this paper
• Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation.

  1998cited by this paper

• Enhanced glycolysis induced by activation of AKT/NF-κB signaling pathway contributes to doxorubicin resistance in DLBCL.

  2025cites this paper
• O-6-Methylguanine-DNA Methyltransferase, C-MYC, and EBER Status in Diffuse Large B-Cell Lymphoma of Central Nervous System

  2024cites this paper
• Application of next-generation sequencing in diffuse large B-cell lymphoma.

  2023cites this paper
• "Unraveling the Molecular Landscape: A Comparative Analysis of PI3K and MAPK Signaling Pathways in Plasmablastic Lymphoma and Diffuse Large B-cell Lymphoma with Therapeutic Implications”

  2023cites this paper
• Altered pathways and targeted therapy in double hit lymphoma

  2022cites this paper
• Distinct microRNA expression signatures of primary and secondary central nervous system lymphomas

  2021cites this paper
• Distinct microRNA expression signatures of primary and secondary central nervous system lymphomas.

  2021cites this paper
• LYNX (LYmphoid NeXt-generation sequencing) panel: a comprehensive capture-based sequencing tool for the analysis of prognostic and predictive markers in lymphoid malignancies.

  2021cites this paper
• Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis

  2021cites this paper
• Genome instability and lymphoma.

  2021cites this paper
• Impact of Omission/Reduction of Vincristine From R-CHOP in Treatment of DLBCL.

  2020cites this paper
• Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma.

  2020cites this paper
• EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B‐cell lymphoma

  2020cites this paper
• Epigenetic regulation of miR-518a-5p-CCR6 feedback loop promotes both proliferation and invasion in diffuse large B cell lymphoma

  2020cites this paper
• Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status

  2019cites this paper
• Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma.

  2019cites this paper
• As the world turns, evolving lymphoma classifications - past, present and future.

  2019cites this paper
• Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma – MCT1 as potential target in diffuse large B cell lymphoma

  2019cites this paper
• Integrated analysis of 10 lymphoma datasets identifies E2F8 as a key regulator in Burkitt's lymphoma and mantle cell lymphoma.

  2019cites this paper
• Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment.

  2018cites this paper
• Expression of exportin-1 in diffuse large B-cell lymphoma: immunohistochemistry and TCGA analyses.

  2018cites this paper
• Germinal center B-cell-like diffuse Large B-cell Lymphoma (GCB) DLBCL

  2018cites this paper
• Diffuse large B-cell lymphoma.

  2018cites this paper
• Emerging roles for long noncoding RNAs in B-cell development and malignancy.

  2017influential citation